1-(3-乙氧基苯基)-2-(4-甲基苯基)-1H-咪唑-4-羧酸 | 954382-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(3-乙氧基苯基)-2-(4-甲基苯基)-1H-咪唑-4-羧酸
• 英文名称: 1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazole-4-carboxylic acid
• 英文别名: 1-(3-ethoxyphenyl)-2-p-tolyl-1H-imidazole-4-carboxylic acid；1-(3-ethoxyphenyl)-2-(4-methylphenyl)imidazole-4-carboxylic acid
• CAS: 954382-59-3
• 化学式: C₁₉H₁₈N₂O₃
• 分子量: 322.364
• InChiKey: YAONDRCTQAAAHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  1-(3-乙氧基苯基)-2-(4-甲基苯基)-1H-咪唑-4-羧酸 在 sodium hydroxide 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 11.0h， 生成 3-{4-[1-(3-ethoxyphenyl)-2-p-tolyl-1H-imidazole-4-carbonyl]piperazin-1-yl}naphthalene-1-carboxylic acid
  参考文献：
  名称：

  A Rapid, Large-Scale Synthesis of a Potent Cholecystokinin (CCK) 1R Receptor Agonist

  摘要：

  The development of a scalable synthesis of a potent cholecystokinin (CCK) 1R receptor agonist is described. The focus on a rapid short-term delivery rather than longer-term development allowed for the preparation of multihundred gram quantities to support aggressive timelines and evaluate safety and pharmacological studies. Key improvements involved streamlining the preparation of imidazole acid 7 and discovery of a more efficient preparation of naphthyl piperazine fragment 23, including an improved preparation of 3-bromonaphthallic anhydride 16.

  DOI：

  10.1021/op800176e
• 作为产物：
  描述：

  间氨基苯乙醚 在 sodium hexamethyldisilazane 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 4.0h， 生成 1-(3-乙氧基苯基)-2-(4-甲基苯基)-1H-咪唑-4-羧酸
  参考文献：
  名称：

  A Rapid, Large-Scale Synthesis of a Potent Cholecystokinin (CCK) 1R Receptor Agonist

  摘要：

  The development of a scalable synthesis of a potent cholecystokinin (CCK) 1R receptor agonist is described. The focus on a rapid short-term delivery rather than longer-term development allowed for the preparation of multihundred gram quantities to support aggressive timelines and evaluate safety and pharmacological studies. Key improvements involved streamlining the preparation of imidazole acid 7 and discovery of a more efficient preparation of naphthyl piperazine fragment 23, including an improved preparation of 3-bromonaphthallic anhydride 16.

  DOI：

  10.1021/op800176e

文献信息

• Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators
  申请人：Berger Richard

  公开号：US20090118300A1

  公开（公告）日：2009-05-07

  Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

  某些新型取代咪唑4-羧酰胺是人类胆囊收缩素受体的配体，特别是人类胆囊收缩素-1受体（CCK-1R）的选择性配体。因此，它们可用于治疗、控制或预防对CCK-1R调节敏感的疾病和疾病，如肥胖症和糖尿病。
• Substituted Imidazole-4-Carboxamides as Cholecystokinin -1 Receptor Modulators
  申请人：Duffy Joseph L.

  公开号：US20090281117A1

  公开（公告）日：2009-11-12

  Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

  某些新型取代咪唑4-羧酰胺是人类胆囊收缩素受体的配体，特别是人类胆囊收缩素-1受体（CCK-1R）的选择性配体。因此，它们可用于治疗、控制或预防对CCK-1R调节有响应的疾病和障碍，如肥胖症和糖尿病。
• Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07858629B2

  公开（公告）日：2010-12-28

  Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

  某些新型取代咪唑4-羧酰胺是人类胆囊收缩素受体的配体，特别是人类胆囊收缩素-1受体（CCK-1R）的选择性配体。它们因此可用于治疗、控制或预防对CCK-1R调节敏感的疾病和障碍，如肥胖症和糖尿病。
• Substituted imidazole-4-carboxamides as cholecystokinin-1 receptor modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07759352B2

  公开（公告）日：2010-07-20

  Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

  某些新型取代咪唑4-羧酰胺是人类胆囊收缩素受体的配体，特别是人类胆囊收缩素-1受体（CCK-1R）的选择性配体。因此，它们可用于治疗、控制或预防对CCK-1R调节敏感的疾病和疾病，如肥胖症和糖尿病。
• SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS
  申请人：Berger Richard

  公开号：US20100311649A1

  公开（公告）日：2010-12-09

  Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R , such as obesity, and diabetes.

  某些新型取代咪唑-4-羧酰胺是人胆囊收缩素受体的配体，特别是人胆囊收缩素-1受体(CCK-1R)的选择性配体。因此，它们可用于治疗、控制或预防对CCK-1R调节敏感的疾病和障碍，如肥胖和糖尿病。